CY1108503T1 - Dna το οποιο κωδικοποιει τον υποδοχεα snorf25 - Google Patents

Dna το οποιο κωδικοποιει τον υποδοχεα snorf25

Info

Publication number
CY1108503T1
CY1108503T1 CY20081101291T CY081101291T CY1108503T1 CY 1108503 T1 CY1108503 T1 CY 1108503T1 CY 20081101291 T CY20081101291 T CY 20081101291T CY 081101291 T CY081101291 T CY 081101291T CY 1108503 T1 CY1108503 T1 CY 1108503T1
Authority
CY
Cyprus
Prior art keywords
mammalian snorf25
snorf25 receptors
receptors
nucleic acid
methods
Prior art date
Application number
CY20081101291T
Other languages
English (en)
Inventor
James A Bonini
Beth E Borowsky
Nika Adham
Noel Boyle
Thelma O Thompson
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26944658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108503(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1108503T1 publication Critical patent/CY1108503T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Αυτή η ευρεσιτεχνία παρέχει τα απομονωμένα νουκλεϊκά οξέα που κωδικοποιούν τους υποδοχείς SNORF25 του τύπου των θηλαστικών, τους καθαρισμένους υποδοχείς SNORF25 του τύπου των θηλαστικών, τους φορείς που περιλαμβάνουν το νουκλεϊκό οξύ που κωδικοποιεί τους υποδοχείς SNORF25 του τύπου των θηλαστικών, τα κύτταρα που περιλαμβάνουν τέτοιους φορείς, τα αντισώματα που απευθύνονται στους υποδοχείς SNORF25 των θηλαστικών, στους ανιχνευτές των νουκλεϊκών οξέων που είναι χρήσιμοι για την ανίχνευση του νουκλεϊκού οξέος που κωδικοποιεί τους υποδοχείς SNORF25 του τύπου των θηλαστικών, τα αντιαγγελιαφόρα ολιγονουκλεοτίδια συμπληρωματικά με τις μοναδικές αλληλουχίες του νουκλεϊκού οξέος που κωδικοποιούν τους υποδοχείς SNORF25 του τύπου των θηλαστικών, τα διαγονιδιακά μη ανθρώπινα ζώα που εκφράζουν το DNA που κωδικοποιεί τους φυσιολογικούς ή τους μεταλλακτούς υποδοχείς SNORF25 του τύπου των θηλαστικών, τις μεθόδους θεραπείας μίας ανωμαλίας που συνδέεται με την ενεργότητα των υποδοχέων SNORF25 του τύπου των θηλαστικών, καθώς και τις μεθόδους προσδιορισμού των ενώσεων προς τους υποδοχείς SNORF25 του τύπου των θηλαστικών, τις μεθόδους ταυτοποίησης των αγωνιστών και ανταγωνιστών των υποδοχέων SNORF25 του τύπου των θηλαστικών και των αγωνιστών και ανταγωνιστών που ταυτοποιήθηκαν κατ' αυτόν τον τρόπο.
CY20081101291T 1999-02-22 2008-11-12 Dna το οποιο κωδικοποιει τον υποδοχεα snorf25 CY1108503T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25537699A 1999-02-22 1999-02-22
US09/387,699 US6221660B1 (en) 1999-02-22 1999-08-13 DNA encoding SNORF25 receptor
EP00908748A EP1075493B1 (en) 1999-02-22 2000-02-22 Dna encoding snorf25 receptor

Publications (1)

Publication Number Publication Date
CY1108503T1 true CY1108503T1 (el) 2014-04-09

Family

ID=26944658

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101291T CY1108503T1 (el) 1999-02-22 2008-11-12 Dna το οποιο κωδικοποιει τον υποδοχεα snorf25

Country Status (12)

Country Link
US (3) US6221660B1 (el)
EP (1) EP1075493B1 (el)
JP (2) JP2002539772A (el)
AT (1) ATE405589T1 (el)
AU (1) AU777247B2 (el)
CA (1) CA2362906A1 (el)
CY (1) CY1108503T1 (el)
DE (1) DE60039948D1 (el)
DK (1) DK1075493T3 (el)
ES (1) ES2312333T3 (el)
PT (1) PT1075493E (el)
WO (1) WO2000050562A2 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
EP1849866B1 (en) * 1998-11-20 2008-05-21 Arena Pharmaceuticals, Inc. Human orphan G protein-coupled receptor RUP3
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
WO2000073449A1 (en) 1999-05-28 2000-12-07 Synaptic Pharmaceutical Corporation Dna encoding snorf33 receptor
GB9923177D0 (en) * 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
EP1226250A2 (en) * 1999-11-03 2002-07-31 MERCK PATENT GmbH Gpcr-kd5 polypeptides and dna sequences thereof
EP1237909A2 (en) * 1999-11-16 2002-09-11 PHARMACIA & UPJOHN COMPANY Human g protein-coupled receptors
AU6744501A (en) * 2000-05-18 2001-11-26 Bayer Aktiengesellschaft Regulation of human dopamine-like g protein-coupled receptor
EP1338651B9 (en) * 2000-12-01 2007-05-09 Astellas Pharma Inc. Method of screening remedy for diabetes
US20030064381A1 (en) * 2001-03-07 2003-04-03 Feder John N. Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY26, expressed highly in testis and gastrointestinal tissues
WO2002077001A2 (en) * 2001-03-09 2002-10-03 Tularik Inc. Novel receptors
US7053121B2 (en) * 2001-03-19 2006-05-30 Trustees Of The University Of Pennsylvania Compositions and methods for regulating circadian rhythms
EP2272946B9 (en) 2002-02-25 2015-06-24 Vaxiion Therapeutics, LLC Minicell compositions and methods
US20050191612A1 (en) * 2002-09-11 2005-09-01 Takahide Ohishi Method of screening insulin content enhancer
US20030143590A1 (en) * 2002-11-18 2003-07-31 Shyam Ramakrishnan Regulation of human dopamine-like g protein- coupled receptor
WO2004099419A2 (en) * 2003-04-30 2004-11-18 Arena Pharmaceuticals, Inc. Methods and compositions for identifying modulators of g protein-coupled receptors
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
DE602004031605D1 (de) * 2003-05-20 2011-04-14 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
US7309589B2 (en) * 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
KR20070091038A (ko) * 2004-12-24 2007-09-06 프로시디온 리미티드 Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7306203B2 (en) * 2005-01-28 2007-12-11 Platt Robert E Post assembly and spacer for use therewith
WO2006113236A2 (en) * 2005-04-14 2006-10-26 Cornell Research Foundation, Inc. Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
EP2369341A3 (en) * 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
EA015129B1 (ru) 2007-01-04 2011-06-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20100286112A1 (en) * 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
CA2697551C (en) * 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
CL2009000782A1 (es) * 2008-03-31 2010-04-30 Metabolex Inc Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
GB0812642D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010004344A1 (en) * 2008-07-10 2010-01-14 Prosidion Limited Piperidine gpcr agonists
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
US8742117B2 (en) 2008-12-24 2014-06-03 Cadila Healthcare Limited Oxime derivatives
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010118404A2 (en) * 2009-04-09 2010-10-14 California Institute Of Technology Methods for creating or identifying compounds that bind tumor necrosis factor alpha
AU2010261341B2 (en) 2009-06-18 2014-02-06 Cadila Healthcare Limited Novel GPR 119 agonists
KR20120046188A (ko) * 2009-06-24 2012-05-09 뉴로크린 바이오사이언시즈 인코퍼레이티드 신규 화합물, 약제학적 조성물 및 이에 관련된 방법
WO2010149685A1 (en) * 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
JP2012228180A (ja) * 2009-09-02 2012-11-22 Panasonic Corp 脂質二重膜の産生方法、化学物質を検知可能とする方法、細胞、カリウムイオンを輸送する方法、および化学物質を検知または定量する方法
JP2012228181A (ja) * 2009-09-02 2012-11-22 Panasonic Corp 脂質二重膜の産生方法、化学物質を検知可能とする方法、細胞、カリウムイオンを輸送する方法、および化学物質を検知または定量する方法
US8410127B2 (en) * 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
SG188547A1 (en) 2010-10-08 2013-04-30 Cadila Healthcare Ltd Novel gpr 119 agonists
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053337A (en) 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
US5661024A (en) 1989-10-31 1997-08-26 Synaptic Pharmaceutical Corporation DNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5155218A (en) 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
ES2085246T1 (es) 1991-12-02 1996-06-01 Synaptic Pharma Corp Adn que codifica un receptor humano 5-ht1e y utilizaciones del mismo.
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
WO1993025677A1 (en) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
US5861309A (en) 1992-09-25 1999-01-19 Synaptic Pharmaceutical Corporation DNA endoding human alpha 1 adrenergic receptors
US5472866A (en) 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5516653A (en) 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
CA2348688A1 (en) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
EP1849866B1 (en) 1998-11-20 2008-05-21 Arena Pharmaceuticals, Inc. Human orphan G protein-coupled receptor RUP3
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US20040224314A1 (en) 1999-12-10 2004-11-11 Neil Burford G-protein coupled receptors

Also Published As

Publication number Publication date
CA2362906A1 (en) 2000-08-31
DE60039948D1 (de) 2008-10-02
EP1075493B1 (en) 2008-08-20
ATE405589T1 (de) 2008-09-15
DK1075493T3 (da) 2009-01-12
EP1075493A2 (en) 2001-02-14
JP2002539772A (ja) 2002-11-26
ES2312333T3 (es) 2009-03-01
US6468756B1 (en) 2002-10-22
JP2010063457A (ja) 2010-03-25
US20030139590A1 (en) 2003-07-24
EP1075493A4 (en) 2004-10-27
US7416848B2 (en) 2008-08-26
WO2000050562A3 (en) 2000-12-14
AU777247B2 (en) 2004-10-07
WO2000050562A2 (en) 2000-08-31
AU3003500A (en) 2000-09-14
US6221660B1 (en) 2001-04-24
PT1075493E (pt) 2008-12-03

Similar Documents

Publication Publication Date Title
CY1108503T1 (el) Dna το οποιο κωδικοποιει τον υποδοχεα snorf25
WO2000039279A3 (en) Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
DE69423007D1 (de) Dna codierend für einen menschlichen neuropeptid y/peptid yy/pankreaspolypeptid-rezeptor (y4) und seine verwendung
ES2083344T1 (es) Dna que codifica un receptor 5-ht1f humano y utilizacion del mismo.
ES2059298T3 (es) Adn que codifica receptores humanos de 5-ht1d y utilizaciones del mismo.
WO2002002744A3 (en) Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
Ashman et al. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding
CY1116682T1 (el) Διπλασιασμος-μυϊκης μαζας σε θηλαστικα
WO1997026853A3 (en) Dna encoding galanin galr2 receptors and uses thereof
ATE245197T1 (de) Entwurf diskontinuierlicher sonden unter verwendung von hybritopemapping
JP2005502312A (ja) タンパク質およびそれをコードする核酸
DE69233496D1 (de) Dna kodierend für den menschlichen 5-ht 1e-rezeptor und seine verwendungen
DE69333623D1 (de) Klonierung und expression von gonadotropinreleasing hormon
WO2004064774A3 (en) Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
WO2000073449B1 (en) Dna encoding snorf33 receptor
JP2010502192A5 (el)
DE60130565D1 (de) Pde8a und seine verwendung
WO2003070916A3 (en) Dna encoding snorf44 receptor
US20100136568A1 (en) Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
US20210071251A1 (en) Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) Variants And Uses Thereof
US20090130088A1 (en) Compositions and methods for regulating RNA translation via CD154 CA-dinucleotide repeat
US6946247B1 (en) RNAse probe protection assays in screening for modulators of immunoglobulin germline transcription
Mihalcik Regulation of BAFF-R in B cell ontogeny and malignancy
JP2005508638A (ja) ７１１８、ヒトアルギニンｎ−メチルトランスフェラーゼファミリーメンバーおよびその使用